Engflag

Efinaconazole

Quick links to important sections

Efinaconazole

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Efinaconazole

Efinaconazole is a synthetic compound classified as an azole antifungal agent, developed specifically for topical application against fungal pathogens. It is a modern triazole derivative used in medical practice as a prescription-only monotherapy product. This medicine is defined by its focused action on eliminating specific fungal organisms that affect tissues like the nail and surrounding structures.

Quick Facts

Property Description
Active ingredient Efinaconazole (INN)
Form Topical solution (liquid)
Pharmacological class Azole antifungal agent
Route of administration Topical application
Origin/Status Synthetic, Prescription-Only (Rx)

Efinaconazole Classification and Unique Properties

Efinaconazole is categorized within the high-level pharmacological class of azole antifungals, meaning its core function is to combat fungi. This drug is a potent, single-active-ingredient product, with Efinaconazole (chemical formula C18H24FN3O2) serving as the sole active compound. A primary differentiating factor of Efinaconazole compared to older topical antifungals is its low affinity for keratin. This structural feature contributes to its delivery through the nail plate and into the nail bed.

Composition and Targeted Topical Solution Form

The form of Efinaconazole is a topical solution, which is a clear, liquid preparation intended for direct external use on the nail. This dosage form is critical, as it ensures the concentrated delivery of the active ingredient to the affected area via the topical route of administration. The solution base contains specialized alcohol-based excipients and vehicles engineered to produce a low surface tension. This unique formulation property allows the solution to better wet the nail and spread into the subungual space, directly addressing the challenge of reaching the infection site beneath the nail.

General Purpose and Activity

The general purpose of Efinaconazole is to eliminate the fungal organisms causing infection through a potent, targeted fungicidal activity. This compound achieves its effect by structurally disrupting the fungal cell membrane, which is vital for the organism's survival. Its primary benefit is therefore rooted in providing a means to actively destroy the fungal pathogen, addressing the source of the infection by destabilizing its core cellular architecture.

What side effects are possible with Efinaconazole?

Possible side effects and safety information

The safety profile of Efinaconazole is characterized primarily by localized reactions at the application site, reflecting its topical route of administration. Adverse reactions are classified based on incidence rates observed in clinical trials, with the majority of documented effects falling under the System-Organ-Classes of General Disorders and Administration Site Conditions and Skin and Subcutaneous Tissue Disorders.

Documented Adverse Reactions

The following are officially listed adverse reactions, classified by their frequency in regulatory documentation:

Frequency Classification Common Adverse Reactions (Incidence ge 1%)
Common Ingrown toenail (Onychocryptosis)
Common Application site dermatitis, vesicles, and pain (including burning or stinging)
Frequency Not Known Onychomadesis (nail shedding), Nail discoloration, Application site erythema, and exfoliation

Safety Restrictions and Considerations

Efinaconazole topical solution is contraindicated in patients with a known hypersensitivity to the active ingredient or any component of the formulation. Due to its excipient composition, the solution is flammable and must be kept away from heat and open flame. It is strictly for topical use only on the toenails and surrounding skin and is not intended for oral, ophthalmic, or intravaginal use.

Safety is established in patients 6 years of age and older. For pregnant or nursing women, the regulatory position states that use should be considered only if the potential benefit justifies the potential risk, as human data are not sufficient to fully assess risks.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Efinaconazole Topical Solution addresses overdose primarily within the context of accidental oral ingestion. Due to the low systemic absorption inherent to the topical route of administration, systemic overdose resulting from the intended use is not expected to be dangerous.

Emergency Response and When to Seek Help

Immediate medical help is required when accidental oral ingestion of the solution has occurred. Regulatory guidance explicitly mandates that you seek emergency medical attention or call the Poison Help line immediately following this exposure. This action is critical for observation and management.

Documented Manifestations and Management

No specific systemic symptoms, such as cardiovascular or neurological complications, are documented in the official prescribing information's overdose section. However, the potential for severe local skin reactions at the application site, including severe redness, itching, or swelling of the treated toenail, should prompt contact with a healthcare professional.

In the event of accidental ingestion, if the person is conscious, general first-aid measures include washing out the mouth with water. The overall management for any over-exposure scenario is restricted to symptomatic and supportive treatment, as no specific antidote is known for Efinaconazole. Regulatory information indicates that hospital observation may be required as part of the supportive care protocol.

Therapeutic Uses of Efinaconazole

What Efinaconazole Treats: Main Uses and Benefits

Efinaconazole is used for the management of conditions involving systemic or localized discomfort, specifically onychomycosis, which is a fungal infection of the toenails. This topical medication is applied to address symptoms related to physical discomfort caused by these infections, including those linked to dermatophytes.

This topical solution is used to treat fungal or yeast infections of the toenails. The treatment assists with managing fungal organisms, a process that contributes to easing the overall symptom load and supports the nail as it replaces damaged tissue.

The primary area of use involves addressing fungal disease caused by pathogens such as Trichophyton rubrum and Trichophyton mentagrophytes. It is utilized in situations involving distressing symptoms of fungal nail disease, applied directly to the infection localized within the nail unit. The medication is relevant for managing the underlying infection and supporting the maintenance of functional stability.

It helps address symptom clusters that may become intense or disruptive to the nail structure. These symptoms include nail thickening, discoloration, and the accumulation of debris beneath the nail. Use of the solution contributes to improved comfort during symptomatic periods and may help with issues related to physical discomfort associated with the nail's structural damage.

The therapeutic role is relevant in contexts involving a heightened systemic burden; as a topical approach, it minimizes systemic exposure. This supports patients who require non-systemic options, such as older adults and individuals with diabetes.

Quick Fact: Relief for Nail Structural Damage

Efinaconazole supports the management of nail thickening and brittleness often seen in fungal infections. This assists with maintaining functional stability by addressing the physical deformation of the nail.

Regulatory References

  1. NIH MedlinePlus overview of Efinaconazole

Eligibility and Restrictions for Use

Who Can and Cannot Use Efinaconazole?

This section outlines the official population eligibility and non-eligibility rules for Efinaconazole topical solution, based strictly on government regulatory documents.

Official Eligibility Status

Population Group Regulatory Status
Established Use Adults and pediatric patients 6 years of age and older
Use Not Established Pediatric patients under 6 years of age
Conditional Use (Pregnancy) Permitted only if the potential benefit justifies the potential risk to the fetus
Conditional Use (Lactation) Caution should be exercised when administered to a nursing woman

Contraindications and Restrictions

While the U.S. FDA label does not list any absolute contraindications, certain international regulatory documents prohibit use in patients with known hypersensitivity to Efinaconazole or any component of the formulation.

Efinaconazole is for topical use only and is not indicated for oral, ophthalmic, or intravaginal administration. The official labeling notes that safety and effectiveness have not been studied in certain patient groups, including those with a history of immunosuppression or uncontrolled diabetes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Efinaconazole is a medicine applied topically, and its official interaction profile is defined by minimal systemic absorption. Due to the very low systemic plasma concentrations achieved, official regulatory labeling documents classify the risk for conventional drug-drug interactions as low.

Systemic Drug-Drug Interactions

The regulatory conclusion is that drug-drug interactions are not expected when this topical solution is co-administered with other systemic medicines. This is supported by in vitro studies, which show that Efinaconazole, at therapeutic concentrations, neither inhibits nor induces the activity of Cytochrome P450 (CYP450) enzymes. Therefore, no formal interaction outcomes, such as reduced clearance or increased plasma concentrations of other systemic products, are officially documented in prescribing information.

Restrictions and Other Substances

There are no medicinal products formally listed as contraindicated for co-administration in the FDA label. The only formal contraindication in some regulatory territories is a known hypersensitivity to the active substance or any of the product's excipients. Furthermore, no formal interactions with food, alcohol, or herbal products are documented in the official prescribing information.

Interaction-Related Constraint Official Regulatory Statement
Timing Restriction Patients must avoid using nail polish or cosmetic nail products on the treated toenails during the use of the solution.
Metabolic Risk Not expected to alter drug exposure (AUC/Cmax) of co-administered systemic medicines.

Mechanism of Action

How Efinaconazole Works: The Mechanism of Action

Fungal Cell Membrane Synthesis Blockade

Efinaconazole's core action is the highly selective inhibition of the fungal enzyme Lanosterol 14alpha-demethylase (CYP51A1). This critical molecular blockade directly prevents the biosynthesis of ergosterol, the key structural sterol required for maintaining the integrity and fluidity of the fungal cell membrane. The result is the accumulation of toxic 14alpha-methylated sterol intermediates within the organism, which alters core cellular functions.

Cascade to Fungicidal Activity

The molecular disruption of the cell membrane architecture initiates a rapid cellular cascade: the structural instability leads to increased membrane permeability and leakage of essential cellular contents. This systematic failure of the pathogen's core structure and metabolism produces fungicidal activity, which reflects the physiological consequence of organism destruction due to cellular failure.

Enhanced Trans-ungual Delivery Mechanism

A key element enabling this action is the product's formulation, which features a low surface tension and low affinity for keratin. This physical mechanism ensures the necessary concentration of the active agent penetrates the dense nail plate to reach the infection site, allowing the 14alpha-demethylase inhibition to proceed against the fungal pathogen.

Dosage and Administration Information

How to Use Efinaconazole

Efinaconazole is administered strictly via the topical route as a 10% solution for the treatment of toenail onychomycosis. The solution is explicitly not for oral, ophthalmic, or intravaginal use.

Administration Regimens and Frequency

The standard regimen is the application of the solution to the affected toenail(s) once daily (qDay). This regimen applies to adults and pediatric patients 6 years of age and older. The medication is used as a long-term course of therapy, with an official treatment duration of 48 consecutive weeks.

If a scheduled daily application is missed, the recommended procedure is to apply the solution as soon as the lapse is realized, unless it is nearly time for the next scheduled application, in which case the missed dose should be skipped.

Application Technique and Context

Application of the solution must be preceded by specific preparatory steps and conducted using the integrated flow-through brush applicator. The application must occur on clean, dry toenails, and a waiting period of at least 10 minutes is required after showering, bathing, or washing before application.

The technique requires that the dose is applied to completely cover the entire nail unit, including the toenail surface, the toenail folds, the toenail bed, the hyponychium (skin beneath the free edge), and the undersurface of the toenail plate. This thorough coverage is essential to ensure the medication reaches the site of the infection, which is often located beneath the nail structure.

Recent Clinical Evidence

Efinaconazole topical solution is an azole antifungal studied for the treatment of onychomycosis, a fungal infection of the toenail. Clinical research has primarily focused on its use in patients with mild to moderate disease severity.

Core Efficacy Findings

Two pivotal, 52-week Phase 3 randomized controlled trials (RCTs) evaluated the treatment against a vehicle (placebo) solution. The primary measure of success was complete cure (a composite endpoint defined as 0% clinical involvement and negative mycological tests).

  • Complete Cure Rates: At the end of the 52-week assessment, the complete cure rates observed in the treatment groups ranged from approximately 15% to 18%, compared to 3% to 6% in the vehicle groups across the pooled data. Mycological cure rates (negative microscopy and culture) were reported to be over 50% in the active treatment groups.

Subgroup and Long-Term Data

Analyses of the Phase 3 data and subsequent studies have explored outcomes across different patient groups and for longer durations:

  • Longer Treatment Periods: Studies investigating treatment extended beyond the initial 48 weeks have noted that rates of both mycological and effective cure (mycological cure and le10% affected nail area) continued to increase over time, suggesting ongoing improvement with continuous use.
  • Population Subsets: Efficacy and safety profiles observed in patient subgroups, including older patients (aged 65 and above) and those with greater baseline disease severity, were generally consistent with the overall results from the main trials. No significant increase in treatment risk was observed in older patients.
  • Combination Therapy: Laboratory (in vitro) studies have explored the combined effect of efinaconazole with oral antifungals like terbinafine or itraconazole, finding no antagonistic effects and suggesting potential synergistic activity against some strains of fungi. Clinical studies investigating topical efinaconazole combined with physical treatments like grinding or drilling have reported greater clinical improvement compared to topical treatment alone.

Frequently Asked Questions (FAQ)

Common questions about Efinaconazole (FAQ)

Q: Why is Efinaconazole often prescribed instead of oral medications?

Official product information indicates that Efinaconazole has low systemic absorption after topical application, meaning very little of the medicine enters the bloodstream. Because of this, clinically important drug interactions are unlikely. This low absorption profile is a key difference compared to oral antifungal medicines.

Q: Can Efinaconazole be used by people with other health conditions like diabetes?

Studies and official information indicate that the safety and effectiveness of Efinaconazole have not been established in patients with certain complex medical histories, including those with a history of immunosuppression or uncontrolled diabetes.

Q: How effective is Efinaconazole in treating severe toenail infections?

The primary research focused on patients with mild to moderate toenail disease severity. While the medicine’s official research centers on these groups, official documents note that results in patient subgroups with greater baseline disease severity were generally consistent with the overall findings from the main trials.

Q: Is Efinaconazole the same type of medication as over-the-counter antifungals?

Efinaconazole is classified as a modern azole antifungal medicine that requires a prescription. Most common over-the-counter antifungal products are generally different drug classes or older azole derivatives, meaning they may not share the same mechanism of action or formulation properties.

Q: Does Efinaconazole work for all types of nail fungus?

The medicine is specifically indicated for the topical treatment of toenail onychomycosis caused by the two dermatophyte fungi: Trichophyton rubrum and Trichophyton mentagrophytes. This indication focuses its use on eliminating these specific organisms that cause the infection.

Q: Is liver function monitoring or bloodwork required while using Efinaconazole?

Due to the medicine's low systemic absorption following topical application, official labeling does not mention a requirement for routine liver function monitoring or bloodwork.

Q: Do application site side effects, like blisters, mean the treatment should be stopped?

While minor localized reactions are common, official safety information indicates that patients should contact their healthcare professional if a reaction suggesting sensitivity or severe irritation occurs, such as persistent blisters or severe redness.

Q: Can Efinaconazole be used on fingernails or is it only for toenails?

Efinaconazole is officially indicated for the topical treatment of onychomycosis of the toenail(s) only. Official product information states that its use on fingernails has not been established.

Q: What should be done if Efinaconazole solution gets on the surrounding skin?

The application technique requires covering the skin folds around the nail. If severe irritation occurs in the area where the medicine was applied, the official product labeling instructs the patient to contact their healthcare provider.

Q: What happens if Efinaconazole solution is accidentally swallowed?

Because Efinaconazole is formulated for very low systemic absorption, official safety documents note that serious outcomes are not anticipated from accidental ingestion. However, safety documents still advise contacting a Poison Help line or seeking emergency medical attention if the solution is accidentally swallowed.

Q: Is Efinaconazole effective against yeast or non-dermatophyte molds, or just dermatophytes?

The medicine is specifically indicated for two types of dermatophytes. While laboratory data has shown activity against some Candida species (which are yeast), this in vitro activity is not part of the medicine's official labeled indication.

Q: What kind of studies have been conducted on Efinaconazole's safety in children 6 years and older?

Safety and the medicine’s behavior in the body (pharmacokinetics) for children aged 6 to 16 years were established in an open-label, single-arm study. This research is the basis for the medicine being established for use in pediatric patients aged 6 years and older.

Q: Is it necessary to thin or file the nail before applying Efinaconazole?

The official application instructions provided in the regulatory documents do not require any mechanical thinning, filing, or debridement of the nail prior to using the medicine.

Q: What is the importance of cleaning and drying the nail before Efinaconazole application?

Application instructions require the nail to be clean and dry, and to wait at least 10 minutes after washing. These steps are necessary to help ensure the medicine can properly adhere to and penetrate the nail structure.

Q: What is the definition of 'application site dermatitis' for this drug?

In regulatory documents, application site dermatitis refers to localized skin reactions that can occur where the medicine is applied. These reactions are described as a mild form of irritation, redness (erythema), burning, stinging, or pain.

Q: Can Efinaconazole treatment be used alongside a pedicure from a healthcare professional?

Official labeling prohibits the use of nail polish or other cosmetic nail products on the treated toenails during the course of the treatment. This restriction is in place because these products may interfere with the medicine’s ability to penetrate the nail.

How should Efinaconazole be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information defines strict parameters for the storage and handling of Efinaconazole topical solution, primarily due to its temperature sensitivity and flammability.

Classification Official Regulatory Wording
Storage Temperature Store at 20 C to 25 C (68 F to 77 F). Excursions permitted to 15 C to 30 C (59 F to 86 F).
Prohibited Environment Do not freeze. Keep away from heat and flame (Flammable).
Container Rules Keep bottle tightly closed and store in an upright position.
Child Safety Keep Efinaconazole and all medicines out of the reach of children.
Disposal Instructions Do not keep outdated or unused medicine. Consult your healthcare professional on how to properly dispose of any medicine you do not use.

The official labeling mandates that the product be maintained within a Controlled Room Temperature range and protected from freezing to ensure stability. Because the solution is flammable, it must be kept away from all sources of heat and fire. For unused or expired medicine, disposal must follow professional guidance, and the product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Efinaconazole found in:

A-Z Index: